News | May 02, 2026
Dr Lal PathLabs posts strong Q4 FY26 results with 16.6% revenue growth & PAT at Rs. 132 Cr
The company posted revenue of Rs. 703 crore in Q4 FY26
The company posted revenue of Rs. 703 crore in Q4 FY26
The move puts a spotlight on one of psychiatry’s most persistent clinical challenges: misdiagnosis and delay
The renewal covers two versions of the IQOS device and three HEETS tobacco variants
The 4,000-square-foot facility is designed as a hands-on hub where customers can work directly with scientists and engineers
The microbiology unit generated $645 million in revenue in 2025 and sits within Thermo Fisher’s Specialty Diagnostics segment
But acquisition charges drag earnings into loss
The transaction marks a clear portfolio reshuffle for Indoco
His appointment is expected to further strengthen the company’s financial governance and regional operational strategy across South Asia
Market authorization for generic GLP-1 therapy strengthens company’s diabetes portfolio in Canada
Tamir brings more than 20 years of experience in the medical technology sector
Subscribe To Our Newsletter & Stay Updated
